International trial shows aficamten outperforms standard beta-blocker therapy in patients with obstructive hypertrophic cardiomyopathy.
Ajith Nair, MD, Associate Professor of Cardiology-Medicine and member of The Texas Heart Institute at Baylor College of Medicine, was part of an international research team whose findings were recently published in the New England Journal of Medicine.
The article, Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy, reports results from the MAPLE-HCM trial, a double-blind, randomized study comparing the effectiveness of aficamten—a cardiac myosin inhibitor—with metoprolol, the standard beta-blocker therapy, in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
The study found that patients treated with aficamten experienced greater improvements in exercise capacity, symptoms, and key cardiac measurements compared to those who received metoprolol. These results highlight aficamten’s potential to significantly improve quality of life and outcomes for patients with HCM, a condition historically managed with limited options.
Dr. Nair’s contribution to this groundbreaking study underscores The Texas Heart Institute’s ongoing role in advancing innovative therapies for complex cardiovascular diseases.
The published paper can be found here.
Visit U.S. News & World Report
